Background
Patients with glioblastoma face a grim prognosis. Despite recent advancement in neurosurgical technology and neuro-oncology glioblastomas almost invariably progress or recur.learn more about the trial
Objectives
The primary objective of this trial is to compare survival outcome after surgery followed by adjuvant second-line therapy to no surgery followed by second-line therapy in recurrent glioblastoma.learn more about the trial
Latest News
Keep track on the Trial processThank you!
The ReSurge trial could achieve an increasing recruitment rate during the last year. This is great, especially in view of the pandemia which accompanies us for over a year now.[…]
Read moreNew patients in
Also the newly opened sites in Larisa, Erfurt and Mainz could recuit their first patient. Moreover, one more patient was recruited in Lausanne and six in Bern.In total 36 patients[…]
Read moreFirst site in the Netherlands is recruiting
We very welcome Universitair Medische Centra in Amsterdam with their principal investigator Dr. Philip de Witt Hamer to the ReSurge trial team. Not long after recruitment start, the first patient[…]
Read more